The global market size of Therapeutic Peptides is projected to reach USD 58.4 billion by 2028, with a market growth of 6.3% CAGR during the forecast period.
Peptide therapies are polypeptides or peptides (oligomers or short polymers of amino acids) that are used to treat ailments. Peptide treatments replicate the natural functions of peptides such as hormones, neurotransmitters, growth factors, ion channel ligands and anti-infectives. Because peptides can be digested by the body, they are thought to be reasonably safe and well tolerated.
Liraglutide, the most popular diabetic medicine on the market, contains a lipid chain that increases plasma circulation and provides long-term absorption. Liraglutide is a GLP-1 agonist that self-assembles into an alpha-helical structure and should only be consumed once per day. The half-life of liraglutide in blood is prolonged by approximately 13-14 hours due to lipid conjugation of a palmitoyl chain to a lysine residue at position 26.
This is attributed to the ability of the palmitoyl chain to bind albumin non-covalently, delaying the proteolytic action of DPP IV and allowing for rapid renal clearance. The inclusion of the lipid chain could further prolong the half-life by preventing the DPP IV enzyme from sterically degrading.
Lanreotide, an octapeptide, is another peptide that can self-assemble. This drug is a synthetic counterpart to the peptide hormone somatostatin, which is used to relieve acromegaly (a malfunction in which the body produces excessive amounts of growth hormone).
Lanreotide assembles into monodisperse liquid crystalline nanotubes when exposed to water. Are nanotubes composed of dimers that self-assemble into a 2D lattice held together by sheets? antiparallel and side chain connections. Studies of self-assembling amyloid aggregates created by peptide hormones and neuropeptides have provided more insight into how self-assembly, as well as peptide hormones, are linked.
COVID-19 impact analysis
COVID-19 has been tackled using new peptides that have been repurposed as medicines. Researchers around the world are still looking for chemicals that can stop the infection and replication of SARS-CoV-2 or alleviate the symptoms caused by the virus.
The FDA revised its definition of organic to include chemically produced polypeptides with a length greater than 40 amino acids but less than 100 amino acids (synthetic proteins), and synthetic peptides with a length of 40 amino acids or less (synthetic peptides).
There were 21 peptide drugs under development for the treatment of COVID-19, including 15 synthetic peptides in therapies for the treatment of ARDS and other respiratory ailments caused by SARS-Cov-2 infection.
Market growth factors
Growing number of applications
Cardiovascular disease (CVD) is still the leading cause of death and morbidity worldwide. Many interventions are being tested to improve pathological cardiovascular problems, however, there have been few new drugs licensed for the intervention or treatment. Consequently, new techniques for the treatment of CVD are urgently needed.
Treatment of contributing risk factors and underlying mechanisms, such as inflammation, obesity, hyperglycemia, and hypercholesterolemia, is often used to prevent vascular problems. The pharmaceutical industry has traditionally resisted the use of peptides as therapeutic agents due to their limited stability, size, breakdown rate, and poor distribution. However, there has been a resurgence in the development of peptides and their synthetic derivatives for therapeutic intervention in recent years.
Cancer cases are on the rise around the world
Cancer is the second leading cause of death, accounting for a substantial number of deaths worldwide in 2013. The cancer rate in developed countries is significantly higher than in developing countries. The prevalence of known risk factors is expected to increase in these underdeveloped nations due to population growth and aging, as well as higher prevalence of known risk factors.
Lung cancer is the leading cause of cancer death in men worldwide, but only in industrialized countries, while breast cancer is the leading cause of cancer death in developing countries. Somatic genetic mutations that change the function of the proteins they encode have been linked to cancer. Most solid tumors, such as those of the brain, colon, breast, and pancreas, have somatic changes.
Market restrictive factors
Side effects and risks related to peptide therapy
Naturally occurring polypeptides such as hormones, growth factors, and neurotransmitters, as opposed to synthesized peptide drugs, are thought to play an important function in normal physiology. Membrane impermeability and in vivo instability are two major disadvantages of peptide drugs.
Proteolytic degradation of peptide drugs in serum decreases the bioavailable concentration and shortens the half-life of the drug. Routine dosing may be necessary to maintain the medicinal product at a clinically effective concentration. To avoid proteolytic degradation and improve the in vivo half-life of peptide drugs, a variety of chemical modification approaches have been used.
Main topics covered:
Chapter 1. Market Scope and Methodology
Chapter 2. Market overview
126.96.36.199 Market composition and scenario
2.2 Key factors affecting the market
2.2.1 Market drivers
2.2.2 Market Restrictions
Chapter 3. Competitor Analysis – Global
3.1 Cardinal Matrix
3.2 Recent industry-wide strategic developments
3.2.1 Partnerships, collaborations and agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisitions and Mergers
3.2.4 Approvals and Pathways
3.3 Main winning strategies
3.3.1 Percentage Distribution of Major Top Strategies (2018-2022)
Chapter 4. Global Therapeutic Peptides Market by Types
4.1 Global Innovation Market by Regions
4.2 Global Generic Market by Regions
Chapter 5. Global Therapeutic Peptides Market by Delivery Routes
5.1 Global injecting drugs Market by Regions
5.2 Global Pulmonary Market by Regions
5.3 Global Mucous membranes Market by Regions
5.4 Global Oral Market by Regions
5.5 Global Others Market by Regions
Chapter 6. Global Therapeutic Peptides Market by Synthesis Technology
6.1 Global Liquid Phase Peptide Synthesis (LPPS) Market by Regions
6.2 Global Solid Phase Peptide Synthesis (SPPS) Market by Regions
6.3 Global Hybrid Technology Market by Regions
Chapter 7. Global Peptide Therapeutics Market by Type of Manufacturers
7.1 Global Domestic Market by Region
7.2 Global Outsourcing Market by Regions
Chapter 8. Global Peptide Therapeutics Market by Application
8.1 Global Metabolic Market by Regions
8.2 Global Cardiovascular Market by Regions
8.3 Global GIT and Renal Market by Regions
8.4 Global Anti-infectives and Dermatology Market by Regions
8.5 Global Respirators Market by Regions
8.6 Global Central Nervous System Market by Regions
8.7 Global Cancer Market by Regions
8.8 Global Pain Relief Market by Regions
8.9 Global Others Market by Regions
Chapter 9. Global Therapeutic Peptides Market by Regions
Chapter 10. Company Profiles
10.1 Eli Lilly and company
10.1.1 Company overview
10.1.2 Financial analysis
10.1.3 Regional analysis
10.1.4 Research and development expenses
10.1.5 Recent strategies and developments
10.1.5.1 Partnerships, Collaborations and Agreements
10.1.5.2 Acquisitions and Mergers
10.1.5.3 Approvals and Pathways
10.2 AstraZeneca PLCs
10.2.1 Company overview
10.2.2 Financial analysis
10.2.3 Regional analysis
10.2.4 Research and development expenses
10.2.5 Recent strategies and developments
10.2.5.1 Partnerships, Collaborations and Agreements
10.2.5.2 Acquisitions and Mergers
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Company overview
10.3.2 Financial analysis
10.3.3 Regional analysis
10.3.4 Research and development expenses
10.3.5 Recent strategies and developments
10.3.5.1 Product Launches and Product Expansions
10.3.5.2 Approvals and Acquisitions
10.4 Novartis AG
10.4.1 Company overview
10.4.2 Financial analysis
10.4.3 Segmental and regional analysis
10.4.4 Research and development expenses
10.4.5 Recent strategies and developments
10.4.5.1 Acquisitions and Mergers
10.4.5.2 Approvals and Paths
10.5 Pfizer, Inc.
10.5.1 Company overview
10.5.2 Financial analysis
10.5.3 Regional and segmental analysis
10.5.4 Research and development expenses
10.5.5 Recent strategies and developments
10.5.5.1 Acquisitions and Mergers
10.6 Sanofi SA
10.6.1 Company overview
10.6.2 Financial analysis
10.6.3 Segmental and regional analysis
10.6.4 Research and development expenses
10.6.5 Recent strategies and developments
10.6.5.1 Partnerships, Collaborations and Agreements
10.7 GlaxoSmithKline PLCs
10.7.1 Company overview
10.7.2 Financial analysis
10.7.3 Segmental and regional analysis
10.7.4 Research and development expenses
10.8 Takeda Pharmaceutical Company Limited
10.8.1 Company overview
10.8.2 Financial analysis
10.8.3 Regional analysis
10.8.4 Research and development expenses
10.8.5 Recent strategies and developments
10.8.5.1 Partnerships, Collaborations and Agreements
10.8.5.2 Approvals and Pathways
10.9 Lonza Group AG
10.9.1 Company overview
10.9.2 Financial analysis
10.9.3 Segmental and regional analysis
10.9.4 Research and development expenses
10.10. amgen, inc.
10.10.1 Company overview
10.10.2 Financial analysis
10.10.3 Regional analysis
10.10.4 Research and development expenses
10.10.5 Recent strategies and developments
10.10.5.1 Partnerships, Collaborations and Agreements
For more information about this report, please visit https://www.researchandmarkets.com/r/66e04f